Advertisement

Noncardiac Manifestations of Hereditary Amyloidosis

Published:November 08, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.10.007
      The most common forms of cardiac amyloidosis are progressive, life threatening, and underrecognized. Symptoms affect a variety of organs and overlap with those of more common conditions, complicating and postponing diagnosis. Cardiac disease generally determines mortality, but noncardiac manifestations typically surface before cardiac symptoms, often several years before diagnosis. Familiarity with noncardiac manifestations may lead to early diagnosis, enabling treatment and improving prognosis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gertz M
        • Adams D
        • Ando Y
        • Beirão JM
        • Bokhari S
        • Coelho T
        • Comenzo RL
        • Damy T
        • Dorbala S
        • Drachman BM
        • Fontana M
        • Gillmore JD
        • Grogan M
        • Hawkins PN
        • Lousada I
        • Kristen AV
        • Ruberg FL
        • Suhr OB
        • Maurer MS
        • Nativi-Nicolau J
        • Quarta CC
        • Rapezzi C
        • Witteles R
        • Merlini G.
        Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.
        BMC Fam Pract. 2020; 21: 198
        • Gertz MA
        • Dispenzieri A.
        Systemic amyloidosis recognition, prognosis, and therapy: a systematic review.
        JAMA. 2020; 324: 79-89
        • Siddiqi OK
        • Ruberg FL.
        Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment.
        Trends Cardiovasc Med. 2018; 28: 10-21
        • Lane T
        • Fontana M
        • Martinez-Naharro A
        • Quarta CC
        • Whelan CJ
        • Petrie A
        • Rowczenio DM
        • Gilbertson JA
        • Hutt DF
        • Rezk T
        • Strehina SG
        • Caringal-Galima J
        • Manwani R
        • Sharpley FA
        • Wechalekar AD
        • Lachmann HJ
        • Mahmood S
        • Sachchithanantham S
        • Drage EPS
        • Jenner HD
        • McDonald R
        • Bertolli O
        • Calleja A
        • Hawkins PN
        • Gillmore JD.
        Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis.
        Circulation. 2019; 140: 16-26
        • Oubari S
        • Naser E
        • Papathanasiou M
        • Luedike P
        • Hagenacker T
        • Thimm A
        • Rischpler C
        • Kessler L
        • Kimmich C
        • Hegenbart U
        • Schönland S
        • Rassaf T
        • Reinhardt HC
        • Jöckel KH
        • Dürig J
        • Dührsen U
        • Carpinteiro A.
        Impact of time to diagnosis on mayo stages, treatment outcome, and survival in patients with al amyloidosis and cardiac involvement.
        Eur J Haematol. 2021; 107: 449-457
        • Kharoubi M
        • Bézard M
        • Galat A
        • Le Bras F
        • Poullot E
        • Molinier-Frenkel V
        • Fanen P
        • Funalot B
        • Moktefi A
        • Lefaucheur JP
        • Abulizi M
        • Deux JF
        • Lemonnier F
        • Guendouz S
        • Chalard C
        • Zaroui A
        • Audard V
        • Bequignon E
        • Bodez D
        • Itti E
        • Hittinger L
        • Audureau E
        • Teiger E
        • Oghina S
        • Damy T
        History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis.
        ESC Heart Fail. 2021; 8: 5501-5512
        • Milani P
        • Merlini G
        • Palladini G.
        Light chain amyloidosis.
        Mediterr J Hematol Infect Dis. 2018; 10e2018022
        • Muchtar E
        • Gertz MA
        • Kyle RA
        • Lacy MQ
        • Dingli D
        • Leung N
        • Buadi FK
        • Hayman SR
        • Kapoor P
        • Hwa YL
        • Fonder A
        • Hobbs M
        • Gonsalves W
        • Kourelis TV
        • Warsame R
        • Russell S
        • Lust JA
        • Lin Y
        • Go RS
        • Zeldenrust S
        • Rajkumar SV
        • Kumar SK
        • Dispenzieri A.
        A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing.
        Mayo Clin Proc. 2019; 94: 472-483
        • Barrett CD
        • Dobos K
        • Liedtke M
        • Tuzovic M
        • Haddad F
        • Kobayashi Y
        • Lafayette R
        • Fowler MB
        • Arai S
        • Schrier S
        • Witteles RM.
        A changing landscape of mortality for systemic light chain amyloidosis.
        JACC Heart Fail. 2019; 7: 958-966
        • Adams D
        • Ando Y
        • Beirão JM
        • Coelho T
        • Gertz MA
        • Gillmore JD
        • Hawkins PN
        • Lousada I
        • Suhr OB
        • Merlini G.
        Expert consensus recommendations to improve diagnosis of attr amyloidosis with polyneuropathy.
        J Neurol. 2021; 268: 2109-2122
        • Coelho T
        • Maurer MS
        • Suhr OB.
        THAOS – the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
        Curr Med Res Opin. 2013; 29: 63-76
        • Castaño A
        • Narotsky DL
        • Hamid N
        • Khalique OK
        • Morgenstern R
        • DeLuca A
        • Rubin J
        • Chiuzan C
        • Nazif T
        • Vahl T
        • George I
        • Kodali S
        • Leon MB
        • Hahn R
        • Bokhari S
        • Maurer MS.
        Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
        Eur Heart J. 2017; 38: 2879-2887
        • Russo M
        • Obici L
        • Bartolomei I
        • Cappelli F
        • Luigetti M
        • Fenu S
        • Cavallaro T
        • Chiappini MG
        • Gemelli C
        • Pradotto LG
        • Manganelli F
        • Leonardi L
        • My F
        • Sampaolo S
        • Briani C
        • Gentile L
        • Stancanelli C
        • Di Buduo E
        • Pacciolla P
        • Salvi F
        • Casagrande S
        • Bisogni G
        • Calabrese D
        • Vanoli F
        • Di Iorio G
        • Antonini G
        • Santoro L
        • Mauro A
        • Grandis M
        • Di Girolamo M
        • Fabrizi GM
        • Pareyson D
        • Sabatelli M
        • Perfetto F
        • Rapezzi C
        • Merlini G
        • Mazzeo A
        • Vita G.
        Attrv amyloidosis Italian registry: clinical and epidemiological data.
        Amyloid. 2020; 27: 259-265
        • González-López E
        • Gallego-Delgado M
        • Guzzo-Merello G
        • de Haro-Del Moral FJ
        • Cobo-Marcos M
        • Robles C
        • Bornstein B
        • Salas C
        • Lara-Pezzi E
        • Alonso-Pulpon L
        • Garcia-Pavia P.
        Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
        Eur Heart J. 2015; 36: 2585-2594
        • Scully PR
        • Treibel TA
        • Fontana M
        • Lloyd G
        • Mullen M
        • Pugliese F
        • Hartman N
        • Hawkins PN
        • Menezes LJ
        • Moon JC.
        Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement.
        J Am Coll Cardiol. 2018; 71: 463-464
        • Maurer MS
        • Bokhari S
        • Damy T
        • Dorbala S
        • Drachman BM
        • Fontana M
        • Grogan M
        • Kristen AV
        • Lousada I
        • Nativi-Nicolau J
        • Cristina Quarta C
        • Rapezzi C
        • Ruberg FL
        • Witteles R
        • Merlini G.G
        Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis.
        Circ Heart Fail. 2019; 12e006075
        • Castaño A
        • Drachman BM
        • Judge D
        • Maurer MS.
        Natural history and therapy of ttr-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.
        Heart Fail Rev. 2015; 20: 163-178
        • Nativi-Nicolau JN
        • Karam C
        • Khella S
        • Maurer MS.
        Screening for attr amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness.
        Heart Fail Rev. 2022; 27: 785-793
        • Adams D
        • Algalarrondo V
        • Polydefkis M
        • Sarswat N
        • Slama MS
        • Nativi-Nicolau J.
        Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.
        Orphanet J Rare Dis. 2021; 16: 411
        • Buxbaum JN
        • Ruberg FL.
        Transthyretin V122i (pv142i)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans.
        Genet Med. 2017; 19: 733-742
        • Parker MM
        • Damrauer SM
        • Tcheandjieu C
        • Erbe D
        • Aldinc E
        • Hawkins PN
        • Gillmore JD
        • Hull LE
        • Lynch JA
        • Joseph J
        • Ticau S
        • Flynn-Carroll AO
        • Deaton AM
        • Ward LD
        • Assimes TL
        • Tsao PS
        • Chang KM
        • Rader DJ
        • Fitzgerald K
        • Vaishnaw AK
        • Hinkle G
        • Nioi P.
        Association of the transthyretin variant v122i with polyneuropathy among individuals of african ancestry.
        Sci Rep. 2021; 11: 11645
        • Skrahina V
        • Grittner U
        • Beetz C
        • Skripuletz T
        • Juenemann M
        • Krämer HH
        • Hahn K
        • Rieth A
        • Schaechinger V
        • Patten M
        • Tanislav C
        • Achenbach S
        • Assmus B
        • Knebel F
        • Gingele S
        • Skrahin A
        • Hartkamp J
        • Förster TM
        • Roesner S
        • Pereira C
        • Rolfs A.
        Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
        Ann Med. 2021; 53: 1787-1796
        • Milandri A
        • Farioli A
        • Gagliardi C
        • Longhi S
        • Salvi F
        • Curti S
        • Foffi S
        • Caponetti AG
        • Lorenzini M
        • Ferlini A
        • Rimessi P
        • Mattioli S
        • Violante FS
        • Rapezzi C.
        Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies.
        Eur J Heart Fail. 2020; 22: 507-515
        • Papoutsidakis N
        • Miller EJ
        • Rodonski A
        • Jacoby D.
        Time course of common clinical manifestations in patients with transthyretin cardiac amyloidosis: delay from symptom onset to diagnosis.
        J Card Fail. 2018; 24: 131-133
        • Rapezzi C
        • Merlini G
        • Quarta CC
        • Riva L
        • Longhi S
        • Leone O
        • Salvi F
        • Ciliberti P
        • Pastorelli F
        • Biagini E
        • Coccolo F
        • Cooke RM
        • Bacchi-Reggiani L
        • Sangiorgi D
        • Ferlini A
        • Cavo M
        • Zamagni E
        • Fonte ML
        • Palladini G
        • Salinaro F
        • Musca F
        • Obici L
        • Branzi A
        • Perlini S.
        Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.
        Circulation. 2009; 120: 1203-1212
        • Zegri-Reiriz I
        • de Haro-Del Moral FJ
        • Dominguez F
        • Salas C
        • de la Cuadra P
        • Plaza A
        • Krsnik I
        • Gonzalez-Lopez E
        • Garcia-Pavia P.
        Prevalence of cardiac amyloidosis in patients with carpal tunnel syndrome.
        J Cardiovasc Transl Res. 2019; 12: 507-513
        • Sperry BW
        • Reyes BA
        • Ikram A
        • Donnelly JP
        • Phelan D
        • Jaber WA
        • Shapiro D
        • Evans PJ
        • Maschke S
        • Kilpatrick SE
        • Tan CD
        • Rodriguez ER
        • Monteiro C
        • Tang WHW
        • Kelly JW
        • Seitz WH
        • Jr Hanna M
        Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release.
        J Am Coll Cardiol. 2018; 72: 2040-2050
        • Geller HI
        • Singh A
        • Alexander KM
        • Mirto TM
        • Falk RH.
        Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis.
        JAMA. 2017; 318: 962-963
        • Yanagisawa A
        • Ueda M
        • Sueyoshi T
        • Okada T
        • Fujimoto T
        • Ogi Y
        • Kitagawa K
        • Tasaki M
        • Misumi Y
        • Oshima T
        • Jono H
        • Obayashi K
        • Hirakawa K
        • Uchida H
        • Westermark P
        • Ando Y
        • Mizuta H.
        Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis.
        Mod Pathol. 2015; 28: 201-207
        • Kalichman L
        • Cole R
        • Kim DH
        • Li L
        • Suri P
        • Guermazi A
        • Hunter DJ.
        Spinal stenosis prevalence and association with symptoms: The Framingham Study.
        Spine J. 2009; 9: 545-550
        • Rubin J
        • Alvarez J
        • Teruya S
        • Castano A
        • Lehman RA
        • Weidenbaum M
        • Geller JA
        • Helmke S
        • Maurer MS.
        Hip and knee arthroplasty are common among patients with transthyretin cardiac amyloidosis, occurring years before cardiac amyloid diagnosis: can we identify affected patients earlier?.
        Amyloid. 2017; 24: 226-230
        • Gonzalez-Duarte A
        • Valdés-Ferrer SI
        • Cantú-Brito C.
        Characteristics and natural history of autonomic involvement in hereditary attr amyloidosis: a systematic review.
        Clin Auton Res. 2019; 29: 1-9
        • Gonzalez-Duarte A.
        Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
        Clin Auton Res. 2019; 29: 245-251
        • González-Duarte A
        • Barroso F
        • Mundayat R
        • Shapiro B.
        Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS).
        Auton Neurosci. 2019; 222102590
        • Hussain Y.
        Variable presentation of hereditary transthyretin-mediated amyloidosis at a single center.
        J Clin Neuromuscul Dis. 2021; 23: 7-17
        • Lozeron P
        • Mariani LL
        • Dodet P
        • Beaudonnet G
        • Théaudin M
        • Adam C
        • Arnulf B
        • Adams D.
        Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy.
        Neurology. 2018; 91: e143-e152
        • Rusescu BV
        • Kerschen P
        • Diederich NJ.
        Scalloped pupil in a patient with familial amyloid polyneuropathy.
        JAMA Neurol. 2018; 75: 1435-1436
        • Ebenezer GJ
        • Liu Y
        • Judge DP
        • Cunningham K
        • Truelove S
        • Carter ND
        • Sebastian B
        • Byrnes K
        • Polydefkis M.
        Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
        Ann Neurol. 2017; 82: 44-56
        • Ruberg FL
        • Grogan M
        • Hanna M
        • Kelly JW
        • Maurer MS.
        Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review.
        J Am Coll Cardiol. 2019; 73: 2872-2891
        • Waldmeier D
        • Herzberg J
        • Stephan FP
        • Seemann M
        • Arenja N.
        Advanced imaging in cardiac amyloidosis.
        Biomedicines. 2022; 10: 903